Heart Disease News and Research

Latest Heart Disease News and Research

Impact of cancer treatment on cardiovascular function

For the past two decades, cancer therapy has become more sophisticated and effective, resulting in an ever-expanding group of long-term cancer survivors. There is also a growing awareness of the potentially negative effects of cancer treatment on the heart and the management of cardiac disease during and after cancer therapy.

22 Sep 2010

Sun Pharma completes acquisition of controlling stake in Taro

Sun Pharmaceutical Industries Ltd. today announced that it has completed the acquisition of a controlling stake in Taro Pharmaceutical Industries Ltd. pursuant to the Option Agreement entered into in 2007 with Taro's controlling shareholders led by Taro's Chairman, Dr. Barrie Levitt.

22 Sep 2010

High dose aspirin effective for treatment of severe headache and migraine

An inexpensive, hundred-year-old therapy for pain - aspirin - is effective in high doses for the treatment of severe headache and migraine caused by drug withdrawal, according to a new study by researchers with the UCSF Headache Center. Study participants were administered aspirin through an IV and 25 percent of the time they reported a significant reduction in pain - three points on the 10-point pain scale.

22 Sep 2010

Biodegradable polymers represent future of stent design

Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting. The results were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

21 Sep 2010

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

Boston Scientific Corporation today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with diabetes and those experiencing an acute myocardial infarction (AMI), or heart attack.

21 Sep 2010

Lehigh Valley Health Network automates IRB processes with Click Commerce eResearch Portal software

Click Commerce, the pioneer in customer-configurable solutions for the business of research, announced today that Lehigh Valley Health Network (LVHN) will use the company's eResearch Portal software to automate its Institutional Review Board (IRB) processes, which monitor the safe and ethical conduct of research involving human subjects.

21 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

Volcano to end distribution agreement with Fukuda Desnhi in Japan

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today it has reached an agreement with Fukuda Desnhi Co., Ltd. to end its distribution agreement in Japan.

21 Sep 2010

FDA grants orphan drug designation for MultiStem stem cell therapy

Athersys, Inc. announced today that MultiStem, Athersys' multipotent adult progenitor stem cell therapy, has been granted orphan drug designation by the U. S. Food and Drug Administration for the prevention of graft vs. host disease (GvHD).

21 Sep 2010

Tips to protect physical health

Fifteen years ago, the non-profit Educational Television Network created Healthy Aging Month to focus attention on the positive aspects of getting older and to encourage people to learn how to increase longevity and avoid preventable declines in physical, mental and emotional health. Healthy aging is of particular interest as life expectancy in the United States continues to rise. According to the Centers for Disease Control and Prevention, in 2007 the life expectancy was 75.4 for men and 80.4 for women .

21 Sep 2010

ADI releases World Alzheimer Report 2010

The World Alzheimer Report 2010 was released today to mark World Alzheimer's Day and heighten awareness of the global economic impact of Alzheimer's disease and related dementias.

21 Sep 2010

NIGMS director wins 2011 ASBMB Public Service Award

The American Society for Biochemistry and Molecular Biology has named Jeremy M. Berg, director of the National Institute of General Medical Sciences, the winner of the nonprofit's 2011 ASBMB Howard K. Schachman Public Service Award. Berg will receive the award this evening at an ASBMB Public Affairs Advisory Committee meeting in Arlington, Va.

21 Sep 2010

New MTWA technology is integrated in Quinton Q-Stress cardiac stress systems

Cambridge Heart, Inc., a developer of noninvasive diagnostic tests for cardiac disease, today announced the launch of its Microvolt T-Wave Alternans (MTWA) technology as an integrated part of industry-leading cardiac stress test systems manufactured and distributed by Cardiac Science Corporation. The MTWA technology, which can predict a patient's risk of sudden cardiac arrest (SCA), is now being offered to new and existing users of Cardiac Science's Quinton Q-Stress cardiac stress systems.

21 Sep 2010

VIVUS announces QNEXA study results for obesity treatment

VIVUS, Inc. today announced positive top-line results from a two-year study of QNEXA(phentermine/topiramate) Controlled Release Capsules, an investigational therapy for treatment of obesity, a condition that affects approximately one-third of adult Americans.

21 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Cardiac Science launches MTWA module with Quinton Q-Stress systems

Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, today announced the launch of a Microvolt T-Wave Alternans (MTWA) module that integrates with its industry leading Quinton Q-Stress cardiac stress systems.

21 Sep 2010

Haskell completes St. John Broken Arrow Hospital

The Haskell Company announces it has completed construction on St. John Broken Arrow Hospital and its accompanying medical office building and medical campus in Broken Arrow, Okla., marking the largest design/build health care project in the company’s 45-year history.

21 Sep 2010

Paper highlights need for new studies and guidelines around oxygen therapy during MI

The European Society of Cardiology (ESC) welcomes a paper published today in the Journal of the American College of Cardiology (JACC )(1) highlighting concerns over the use of oxygen therapy during MI in patients with normal oxygen levels. The publication adds to calls for revision of the STEMI guidelines around oxygen therapy and for a prospective, large scale randomised trials, issues that were both first raised in a Cochrane Review published in June.

21 Sep 2010

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.

21 Sep 2010

Global dementia costs hit $604 billion: World Alzheimer Report 2010

The total estimated worldwide costs of dementia are $604 billion in 2010, according to the newly released World Alzheimer Report 2010, The Global Economic Impact of Dementia from Alzheimer's Disease International (ADI), a London based, nonprofit, international federation of 73 national Alzheimer organizations, including the Alzheimer's Association (U.S.).

21 Sep 2010